Mayzent^®
(Siponimod) Novartis

Composition:

•Available in 0.25 mg film-coated tablets corresponding to 0.25 mg siponimod

•Available in 2 mg film-coated tablets corresponding to 2 mg siponimod

Indication(s):

•For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.